Richard Grundy
Division of Child Health, Obstetrics and Gynaecology
The University of Nottingham
United Kingdom
Biography
It is clear that improvement in our ability to cure children with brain tumours and reduce the considerable morbidity will only come through a better understanding of the underlying biology of these varied and presently difficult to treat tumours. The principal aim of my research is based on this philosophy. Our research programme includes the use of DNA and RNA microarray technologies to identify biological correlates of tumour behaviour; to elucidate the underlying molecular alterations of each tumour type and to validate novel targets for the development of new drug therapies. In addition to my research activities at the Children's Brain Tumour Research centre, I also have an active interest in the development and conduct of clinical trials in CNS tumours and am a long standing member of the Children's Cancer Leukaemia Group CNS division. I am Chief investigator of the International Society of Paediatric Oncology Ependymoma study and heavily involved in discussions over the next Ependymoma trial. I am also Chair of the Biology Committee of the UK Paediatric Brain Tumour Consortium and am a Co-Investigator on a number of Children's Cancer Leukaemia, Group Clinical and Biological studies.
Research Interest
We have a major research programme investing the molecualr gemetoc of childhood brain tumours using cutting edge high resolution genetic analysis. We are developing biostatistical infrastructure to maximise the use of the data in our increasingly large data base
Publications
-
ROGERS HA, ESTRANERO J, GUDKA K, GRUNDY RG. The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors. Oncotarget. 8(2), 2083-2095 .(2016).
-
ENGLISH M, GRUNDY RG, PEET A, LOWIS S, WALKER D. Proton beam therapy for medulloblastoma. The Lancet. Oncology. 17(5), e174 .(2016).
-
HAQUE F, VARLET P, PUNTONET J, STORER L, BOUNTALI A, RAHMAN R, GRILL J, CARCABOSO AM, JONES C, LAYFIELD R, GRUNDY RG. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta neuropathologica communications. 5(1), 45.(2017).